Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice
Chih‐Jen Wei, Wei Bu, Laura A. Nguyen, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 643
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Epstein-Barr virus: Biology and clinical disease
Blossom Damania, Shannon C. Kenney, Nancy Raab‐Traub
Cell (2022) Vol. 185, Iss. 20, pp. 3652-3670
Open Access | Times Cited: 237
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications
Kjetil Bjørnevik, Christian Münz, Jeffrey I. Cohen, et al.
Nature Reviews Neurology (2023)
Closed Access | Times Cited: 130
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting
Marc Charabati, Michael A. Wheeler, Howard L. Weiner, et al.
Cell (2023) Vol. 186, Iss. 7, pp. 1309-1327
Open Access | Times Cited: 119
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy
Francesca Aloisi, Gavin Giovannoni, Marco Salvetti
The Lancet Neurology (2023) Vol. 22, Iss. 4, pp. 338-349
Closed Access | Times Cited: 73
Epstein–Barr virus as a potentiator of autoimmune diseases
William H. Robinson, Shady Younis, Zelda Z. Love, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 11, pp. 729-740
Closed Access | Times Cited: 19
Urgency and necessity of Epstein-Barr virus prophylactic vaccines
L. Zhong, Claude Krummenacher, Wanlin Zhang, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 55
Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice
Vijayendra Dasari, Lisa K. McNeil, Kirrilee Beckett, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31
A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV
Cong Sun, Yinfeng Kang, Xin‐Yan Fang, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 11, pp. 1882-1897.e10
Closed Access | Times Cited: 27
HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus
Kathryn Lurain, Ramya Ramaswami, Laurie T. Krug, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 3
Closed Access | Times Cited: 11
Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350
M. Gordon Joyce, Wei Bu, Wei‐Hung Chen, et al.
Immunity (2025)
Open Access | Times Cited: 1
Epidemiology of Multiple Sclerosis: Global, Regional, National and Sub-National-Level Estimates and Future Projections
Gulfaraz Khan, Muhammad Jawad Hashim
Journal of Epidemiology and Global Health (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion
Xiao Zhang, Junping Hong, L. Zhong, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 32
Open Access | Times Cited: 38
Virological Markers in Epstein–Barr Virus-Associated Diseases
Julien Lupo, Aurélie Truffot, Julien Andréani, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 656-656
Open Access | Times Cited: 19
Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents
L. Zhong, Wanlin Zhang, Claude Krummenacher, et al.
Trends in Microbiology (2023) Vol. 31, Iss. 8, pp. 788-804
Open Access | Times Cited: 19
Treatment of Epstein-Barr Virus infection in immunocompromised patients
Martyna Pociupany, Robert Snoeck, Daan Dierickx, et al.
Biochemical Pharmacology (2024) Vol. 225, pp. 116270-116270
Closed Access | Times Cited: 8
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection
L. Zhong, Wanlin Zhang, Hong Liu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Global burden and economic impact of vaccine-preventable cancer mortality
Goran Benčina, Edward Oliver, Anne Meiwald, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. sup2, pp. 9-19
Open Access | Times Cited: 6
The Role of Microorganisms in the Etiopathogenesis of Demyelinating Diseases
Jessica Frau, Giancarlo Coghe, Lorena Lorefice, et al.
Life (2023) Vol. 13, Iss. 6, pp. 1309-1309
Open Access | Times Cited: 15
Ferritin-based nanomedicine for disease treatment
Yuanjun Zhu, Yuefeng Zhu, Tianmiao Cao, et al.
Medical Review (2023) Vol. 3, Iss. 1, pp. 49-74
Open Access | Times Cited: 13
Protein Nanoparticles as Vaccine Platforms for Human and Zoonotic Viruses
Kush Kumar Pandey, Bikash R. Sahoo, Asit K. Pattnaik
Viruses (2024) Vol. 16, Iss. 6, pp. 936-936
Open Access | Times Cited: 5
Next-Generation Vaccine Development with Nanomaterials: Recent Advances, Possibilities, and Challenges
Shamitha Shetty, Pablo Cordero Alvarado, Deleah Pettie, et al.
Annual Review of Biomedical Engineering (2024) Vol. 26, Iss. 1, pp. 273-306
Closed Access | Times Cited: 5
Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens
Marija Rozman, Petra Korać, Karlo Jambrosic, et al.
Pathogens (2022) Vol. 11, Iss. 8, pp. 864-864
Open Access | Times Cited: 21
Identification of polyvalent passive vaccine candidates from egg yolk antibodies (IgY) of important outer membrane proteins of Aeromonas hydrophila in fish
Xiang Liu, Chao Jia, Huihui Xiao, et al.
Aquaculture Reports (2024) Vol. 35, pp. 102002-102002
Open Access | Times Cited: 4
Recent advances in animal models of lymphomagenesis caused by human γ-herpesviruses
Christian Münz
Current Opinion in Virology (2025) Vol. 71, pp. 101461-101461
Open Access
A Liposome-Based Nanoparticle Vaccine Induces Effective Immunity Against EBV Infection
Li Ping, Zihang Yu, Ziyi Jiang, et al.
Vaccines (2025) Vol. 13, Iss. 4, pp. 360-360
Open Access
Page 1 - Next Page

Scroll to top